Advertisement

The Influence of Colony-Stimulating Factors on Neutrophil Production, Distribution, and Function

  • J. Milton Gaviria
  • W. Conrad Liles
  • David C. Dale
Chapter
  • 89 Downloads
Part of the Developments in Oncology book series (DION, volume 80)

Abstract

The colony-stimulating factors (ie. interleukin 3, granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor and monocyte/macrophage colony stimulating factor) are a group of glycoproteins that regulate the proliferation and differentiation of hematopoietic precursor cells1–4. In addition to their effects on hematopoiesis, colony-stimulating factors (CSFs) modulate the function of fully mature cells and therefore play an important role in regulating inflammatory responses vital to host defense. Here we review recent information that describes the biological activity of CSFs, particularly focusing on their modulation of neutrophil production, distribution, and function. The spectrum of biological activity of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) is summarized in Table 1.

Keywords

Human Neutrophil Neutrophil Apoptosis Mature Neutrophil Severe Congenital Neutropenia Neutrophil Respiratory Burst 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Metealf D. The granulocyte-macrophage colony-stimulating factors. Science 229: 16–22, 1985.CrossRefGoogle Scholar
  2. 2.
    Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science 236: 1229–1237, 1987.PubMedCrossRefGoogle Scholar
  3. 3.
    Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 78: 2791–2808, 1991.PubMedGoogle Scholar
  4. 4.
    Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and ranulocyte-macrophage colony-stimulating factor. N Engl J Med 327: 28–35, 1992.PubMedCrossRefGoogle Scholar
  5. 5.
    Metealf D. The molecular control of normal and leukemic granulocytes and macrophages. Proc R Soc London 230: 389–423, 1987.CrossRefGoogle Scholar
  6. 6.
    Spivak J, Smith RR, Ihle JN. Interleukin 3 promotes the in vitro proliferation of murine pluripotent hematopoietic stem cells. J Clin Invest 76: 1613–1621, 1985.PubMedCrossRefGoogle Scholar
  7. 7.
    Lord BI, Molineux G, Pojda Z, et al. Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivo. Blood 77: 2154–2159, 1991.PubMedGoogle Scholar
  8. 8.
    Heyworth CM, Dexter TM, Kan O, Whetton AD. The role of hemopoietic growth factors in self-renewal and differentiation of IL-3 dependent multipotential stem cells. Growth Factors 2: 197–211, 1990.PubMedCrossRefGoogle Scholar
  9. 9.
    Spooncer E, Heyworth CM, Dunn A, Dexter TM. Self renewal and differentiation of interleukin 3 dependent multipotent stem cells are modulated by stromal cells and serum factors. Differentiation 31: 111–118, 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Sonoda Y, Sakabe H, Ohmisono Y, et al. Synergistic actions of stem cell factor and other burst-promoting activities on proliferation of CD34+ highly purified blood progenitors expressing HLA-DR or different levels of c-kit protein. Blood 84: 4099–4106, 1994.PubMedGoogle Scholar
  11. 11.
    Sonoda Y, Kimura T, Sakabe H, et al. Human fll3 ligand acts on myeloid as well as multipotential progenitors derived from purified CD34+ blood progenitors expressing different levels of c-kit protein. Eur J Haematol 58: 257–262, 1997.PubMedCrossRefGoogle Scholar
  12. 12.
    Kimura T, Sakabe H, Tanimukai S, et al. Simultaneous activation of signals through gpl30, c-kit, and interleukin-3 receptor promotes a trilineage blood cell production in the absence of terminally acting lineage-specific factors. Blood 90: 4767–4778, 1997.PubMedGoogle Scholar
  13. 13.
    Smith SL, Bender JG, Maples PB, et al. Expansion of neutrophil precursors and progenitors in suspension cultures of CD34+ cells enriched from human bone marrow. Exp Hematol 21: 870–877, 1993.PubMedGoogle Scholar
  14. 14.
    Broxmeyer HE, Williams DE, Hangoc G, et al. Synergistic myelopoietic actions in vivo after administration to mice of combinations of purified natural murine colony stimulating factor 1, recombinant murine interleukin 3, and recombinant murine granulocyte/macrophage colony stimulating factor. Proc Natl Acad Sci USA 84: 3871–3875, 1987.PubMedCrossRefGoogle Scholar
  15. 15.
    Heyworth CM, Ponting ILO, Dexter TM. The response of hemopoietic cells to growth factors: developmental implications of synergistic interactions. J Cell Sci 91: 239–247, 1988.PubMedGoogle Scholar
  16. 16.
    Aglietta M, Pasquino P, Sanavio F, et al. Granulocyte-macrophage colony-stimulating factor and interleukin 3: target cells and kinetics of response in vivo. Stem Cells 1 l(suppl 2): 83–87, 1993.Google Scholar
  17. 17.
    Lemoli RM, Fortuna A, Fogli M, et al. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. Exp Hematol 23: 1520–1526, 1995.PubMedGoogle Scholar
  18. 18.
    Aglietta M, Sanavio F, Stacchini A, et al. Interleukin 3 in vivo: kinetics of response of target cells. Blood 82: 2054–2061, 1993.PubMedGoogle Scholar
  19. 19.
    Lord BI, Testa NG, Bretti S, et al. Haemopoietic progenitor and myeloid cell kinetics in humans treated with interleukin-3 and granulocyte/macrophage colony-stimulating factor in combination. Int J Cancer 59: 483–490, 1994.PubMedCrossRefGoogle Scholar
  20. 20.
    Ganser A, Ottmann OG, Seipelt G, et al. Effect of long term treatment with recombinant human interleukin-3 in patients with myelodisplastic syndromes. Leukemia 7: 696–701, 1993.PubMedGoogle Scholar
  21. 21.
    Tepler I, Elias A, Kalish L, et al. Effect of recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression. Br J Haematol 87: 678–686, 1994.PubMedCrossRefGoogle Scholar
  22. 22.
    Scadden DT, Levine JD, Bresnahan J, et al. In vivo effects of interleukin 3 in HIV type 1-infected patients with cytopenia. AIDS Res Hum Retrov 11: 731–739, 1995.CrossRefGoogle Scholar
  23. 23.
    Dale DC, Lues WC, Llewellyn C, Price TH. Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil kinetics and function in normal human volunteers. Am J Hematol 57: 7–15, 1998.PubMedCrossRefGoogle Scholar
  24. 24.
    Lord BI, Gurney H, Chang J, et al. Haematopoietic cell kinetics in humans treated with rGM-CSF. Int J Cancer 50:26–31, 1992.PubMedCrossRefGoogle Scholar
  25. 25.
    Crump M, Couture F, Kovacs M, et al. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation. Exp Hematol 21: 405–410, 1993.PubMedGoogle Scholar
  26. 26.
    Albin N, Douay L, Fouillard L, et al. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies. Bone Marrow Transplant 14: 253–259, 1994.PubMedGoogle Scholar
  27. 27.
    Avalos BR, Gasson JC, Hedvat C, et al. Human granulocyte colony-stimulating factor: biologic activities and receptor characterization of hematopoietic cells and small cell lung cancer cell lines. Blood 75: 851–857, 1990.PubMedGoogle Scholar
  28. 28.
    D’Andréa AD. Cytokine receptors in congenital hematopoietic disease. N Engl J Med 330: 839–846, 1994.PubMedCrossRefGoogle Scholar
  29. 29.
    Hammond WP, Csiba E, Canin A, et al. Chronic neutropenia: a new canine model induced by human G-CSF. J Clin Invest 87: 704–710, 1991.PubMedCrossRefGoogle Scholar
  30. 30.
    Lieschke GJ, Grail D, Hodgson G. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84: 1737–1746, 1994.PubMedGoogle Scholar
  31. 31.
    Stanley E, Lieschke GJ, Grail D, et al. Granulocyte-macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but developed a characteristic pulmonary pathology. Proc Natl Acad Sci USA 91: 5592–5596, 1994.PubMedCrossRefGoogle Scholar
  32. 32.
    Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 294: 713–716, 1994.CrossRefGoogle Scholar
  33. 33.
    Cheers C, Haigh AM, Kelso A, et al. Production of colony-stimulating factors (CSFs) during infection: separate determinations of macrophage-, granulocyte-, and multi-CSFs. Infect Immun 56: 247–251, 1988.PubMedGoogle Scholar
  34. 34.
    Dale DC, Lau S, Nash R, et al. Effect of endotoxin on serum granulocyte and granulocyte-macrophage colony-stimulating factor levels in dogs. J Infect Dis 165: 689–694, 1992.PubMedCrossRefGoogle Scholar
  35. 35.
    Kawakami M, Tsutsumi H, Kumakawa T, et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 76: 1962–1974, 1990.PubMedGoogle Scholar
  36. 36.
    Taveira Da Silva AMT, Kaulbach HC, Chuidian FS, et al. Brief report: shock and multiple-organ dysfunction after self-administration of salmonella endotoxin. N Engl J Med 328: 1993 1457–1460.CrossRefGoogle Scholar
  37. 37.
    Cebon J, Layton J, Mäher D, Morstyn G. Endogenous haemopoietic growth factors in neutropenia and infection. Br J Haematol 86: 265–274,1994.PubMedCrossRefGoogle Scholar
  38. 38.
    Price TH, Charta GS, Dale DC. The effect of recombinant granulocyte colony-stimulating factor (G-CSF) on neutrophil kinetics in normal human subjects, (abstract) Blood 80: 350a, 1992.Google Scholar
  39. 39.
    Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 88: 335–340, 1996.PubMedGoogle Scholar
  40. 40.
    Chatta GS, Price TH, Allen RC, Dale DC. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 84: 2923–2929, 1994.PubMedGoogle Scholar
  41. 41.
    Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1: 667–672, 1988.PubMedCrossRefGoogle Scholar
  42. 42.
    Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 327: 28–35, 99–106, 1992.PubMedCrossRefGoogle Scholar
  43. 43.
    Linderman A, Herrmann F, Oster W, et al. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 74: 2633–2651, 1989.Google Scholar
  44. 44.
    Chatta GS, Andrews RG, Roger E, et al. Hematopoietic progenitors and aging: alterations in granulocyte precursors and responsiveness to recombinant human G-CSF, GM-CSF, and IL-3. J Gerontol 48: M207–212, 1993.PubMedCrossRefGoogle Scholar
  45. 44.
    Nielsen SD, Dam-Larsen S, Nielsen C, et al. Recombinant human granulocyte colony-stimulating factor increases circulating CD34-positive cells in patients with AIDS. Ann Hematol 74: 215–220, 1997.PubMedCrossRefGoogle Scholar
  46. 46.
    Lord BI, Bronchud MH, Owens S, et al. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 86: 9499–9503, 1989.PubMedCrossRefGoogle Scholar
  47. 47.
    Lipschitz D, Udupa K, Milton K, Thompson C. Effect of age on hematopoiesis in man. Blood 63: 502–509, 1984.PubMedGoogle Scholar
  48. 48.
    Timmafy M. A comparative study of bone marrow function in young and old individuals. Geront Clin 4: 13–18, 1962.CrossRefGoogle Scholar
  49. 49.
    Motoyoshi K, Takaku F, Maekawa T, et al. Protective effect of partially purified human urinary colony-stimulating factor on granulocytopenia after antitumor chemotherapy. Exp Hematol 14: 1069–1075, 1986.PubMedGoogle Scholar
  50. 50.
    Masaoka T, Motoyoshi K, Takaku F, et al. Administration of human urinary colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 3: 121–127, 1988.PubMedGoogle Scholar
  51. 51.
    Khwaja A, Yong K, Jones HM, et al. The effect of macrophage colony-stimulating factor on haematopoietic recovery after autologous bone marrow transplantation. Br J Haematol 81: 288–295, 1992.PubMedCrossRefGoogle Scholar
  52. 52.
    Laughlin MJ, Kirkpatrick G, Sabiston N, et al. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF. Ann Hematol 67: 267–276, 1993.PubMedCrossRefGoogle Scholar
  53. 53.
    Schuening FG, Neumunaitis J, Appelbaum FR, Storb R. Hematopoietic growth factors after allogeneic marrow transplantation in animal studies and clinical trials. Bone Marrow Transplant 14: S74–S77, 1994.PubMedGoogle Scholar
  54. 54.
    Nemunaitis J. A comparative review of colony-stimulating factors. Drugs 54: 709–729, 1997.PubMedCrossRefGoogle Scholar
  55. 55.
    Zimmerman GA, Prescott SM, McIntyre TM. Endothelial cell interactions with granulocytes: Tethering and signaling molecules. Immunol Today 13: 93–98, 1992.PubMedCrossRefGoogle Scholar
  56. 56.
    Athens JW, Raab SO, Haab OP, et al. Leukokinetic studies. III. The distribution of granulocytes in the blood of normal subjects. J Clin Invest 40: 159–167, 1961.PubMedCrossRefGoogle Scholar
  57. 57.
    Yong KL, Linch DC. Differential effects of granulocyte and granulocyte-macrophage colony-stimulating factors (G- and GM-CSF) on neutrophil adhesion in vitro and in vivo. Eur J Haematol 49: 251–259, 1992.PubMedCrossRefGoogle Scholar
  58. 58.
    Yong KL. Granulocyte colony-stimulating factor (G-CSF) increases neutrophil migration across vascular endothelium independent of an effect on adhesion: comparison with granulocyte-macrophage colony-stimulating factor (GM-CSF). Br J Haematol 94: 40–47, 1996.PubMedCrossRefGoogle Scholar
  59. 59.
    Yong KL, Linch DC. GM-CSF differentially regulates neutrophil migration across IL-1 activated, and nonactivated, human endothelium. J Immunol 150: 2449–2456, 1993.PubMedGoogle Scholar
  60. 60.
    Yuo A, Kitagawa S, Ohsaka A, et al. Recombinant human granulocyte colony-stimulating factor as an activator of human granulocytes: potentiation of responses triggered by receptor-mediated agonists and stimulation of C3bi receptor expression and adherence. Blood 74: 2144–2149, 1989.PubMedGoogle Scholar
  61. 61.
    Okada Y, Kawagishi M, Kusaka M. Effect of recombinant human granulocyte colony-stimulating factor on human neutrophil adherence in vitro. Experientia 46: 1050–1053, 1990.PubMedCrossRefGoogle Scholar
  62. 62.
    Devereux S, Bull HA, Campos-Costa D, et al. Granulocyte-macrophage colony-stimulating factor induced changes in cellular adhesion molecule expression and adhesion to endothelium: in vitro and in vivo studies in man. Br J Haematol 71: 323–330, 1989.PubMedCrossRefGoogle Scholar
  63. 63.
    Yong KL, Rowles PM, Patterson KG, Linch DC. Granulocyte-macrophage colony-stimulating factor induces neutrophil adhesion to pulmonary vascular endothelium in vivo: role of β2 integrins. Blood 80:1565–1575, 1992.PubMedGoogle Scholar
  64. 64.
    Håkansson L, Höglund M, Jonsson U-B, et al. Effects of in vivo administration of G-CSF on neutrophil and eosinophil adhesion. Br J Haematol 98: 603–611, 1997.PubMedCrossRefGoogle Scholar
  65. 65.
    Spiekermann K, Emmendoerffer A, Eisner J, et al. Altered surface marker expression and function of G-CSF induced neutrophils from test subjects and patients under chemotherapy. Br J Haematol 87:31–38, 1994.PubMedCrossRefGoogle Scholar
  66. 66.
    Höglund M, Håkansson L, Venge P. Effects of in vivo administration of G-CSF on neutrophil functions in healthy volunteers. Eur J Haematol 58: 195–202, 1997.PubMedCrossRefGoogle Scholar
  67. 67.
    Yasui K, Tsuno T, Miyabayashi M, et al. Effects of high-dose granulocyte colony-stimulating factoron neutrophil functions. Br J Haematol 92: 571–573, 1996.PubMedCrossRefGoogle Scholar
  68. 68.
    Wang JM, Chen ZG, Colella S, et al. Chemotactic activity of recombinant human granulocyte colony-stimulating factor. Blood 72: 1456–1460, 1988.PubMedGoogle Scholar
  69. 69.
    Bober LA, Grace MJ, Pugliese-Sivo C, et al. The effect of GM-CSF and G-CSF on human neutrophil function. Immunopharmacology 29: 111–119, 1995.PubMedCrossRefGoogle Scholar
  70. 70.
    Wheeler JG, Huffine ME, Childress S, Sikes J. Comparison of colony stimulating factors on in vitro rat and human neutrophil function. Biol Neonate 66: 214–220, 1994.PubMedCrossRefGoogle Scholar
  71. 71.
    Buescher ES, McIlheran SM, Vadhan-Raj S. Effects of in vivo administration of recombinant human granulocyte-macrophage colony-stimulating factor on human neutrophil Chemotaxis and oxygen metabolism (letter). J Infect Dis 158: 1140–1142, 1988.PubMedCrossRefGoogle Scholar
  72. 72.
    Boogaerts M, Meeus P, Verhoef G, et al. Differential effects of IL-3, GM-CSF and G-CSF on preleukemic granulocytes, (abstract) Blood 72: 110a, 1988.Google Scholar
  73. 73.
    Idenbach T, Roesler J, Eisner J, et al. In vitro functions of granulocyte colony-stimulating factor induced neutrophils. In: Freund M, Link H, Schmidt RE, Welte K (eds). Cytokines in Hemopoiesis, Oncology, and AIDS II. Springer. Berlin pp. 521–527, 1992.CrossRefGoogle Scholar
  74. 74.
    Wang JM, Colella S, Allavena P, Mantovani A. Chemotactic activity of human recombinant granulocyte-macrophage colony-stimulating factor. Immunology 60: 439–444, 1987.PubMedGoogle Scholar
  75. 75.
    Weisbart RH, Golde DW. Physiology of granulocyte and macrophage colony-stimulating factors in host disease. Hematol Oncol Clin North Am 3: 401–409, 1989.PubMedGoogle Scholar
  76. 76.
    Turilli I, Bowers D, Aronson I, et al. G-CSF and neutrophil Chemotaxis (letter). Br J Haematol 90: 232–233, 1995.PubMedCrossRefGoogle Scholar
  77. 77.
    Bronchud MH, Potter MR, Morgenstern G, et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer 58: 64–69, 1988.PubMedCrossRefGoogle Scholar
  78. 78.
    Peters WP, Stuart A, Affronti ML, et al. Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans. Blood 72: 1310–1315, 1988.PubMedGoogle Scholar
  79. 79.
    Addison IE, Johnson B, Devereux S, et al. Granulocyte-macrophage colony-stimulating factor may inhibit neutrophil migration in vivo. Clin Exp Immunol 76: 149–153, 1989.PubMedGoogle Scholar
  80. 80.
    Lieschke GJ, Ramenghi U, O’Connor MP, et al. Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. Br J Haematol 82: 589–595, 1992.PubMedCrossRefGoogle Scholar
  81. 81.
    Hammond WP, Price TH, Souza LM, Dale DC. Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med 320: 1306–1311, 1989.PubMedCrossRefGoogle Scholar
  82. 82.
    Bowski AA, Souza L, Kelly F, et al. Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia. N Engl J Med 320: 38–42, 1989.CrossRefGoogle Scholar
  83. 83.
    Toner GC, Jakubowski AA, Crown JP, et al. Colony-stimulating factors and neutrophil migration (letter). Ann Intern Med 110: 846–847, 1989.PubMedGoogle Scholar
  84. 84.
    Montgomery B, Bianco JA, Jacobsen A, Singer JW. Localization of transfused neutrophils to site of infection during treatment with recombinant human granulocyte-macrophage colony-stimulating factor and pentoxifylline (letter). Blood 78: 533–534, 1991.PubMedGoogle Scholar
  85. 85.
    Negrin RS, Haeuber DH, Nagler A, et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I–II trial. Ann Intern Med 110: 976–984, 1989.PubMedGoogle Scholar
  86. 86.
    Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 84: 2068–2101, 1994.PubMedGoogle Scholar
  87. 87.
    Lopez AF, Williamson DJ, Gamble JR, et al. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 78: 1220–1228, 1986.PubMedCrossRefGoogle Scholar
  88. 88.
    Buckle AM, Hogg N. The effect of IFN-γ and colony-stimulating factors on the expression of neutrophil cell membrane receptors. J Immunol 143: 2295–2301, 1989.PubMedGoogle Scholar
  89. 89.
    Haas M, Kerst JM, Van der Schoot CE, et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood 84: 3885–3894, 1994.PubMedGoogle Scholar
  90. 90.
    Katoh M, Shirai T, Shikoshi K, et al. Neutrophil kinetics shortly after initial administration of recombinant human granulocyte colony-stimulating factor: neutrophil alkaline phosphatase activity as an endogenous marker. Eur J Haematol 49: 19–24, 1992.PubMedCrossRefGoogle Scholar
  91. 91.
    Ohsaka A, Kitagawa S, Sakamoto S, et al. In vivo activation of human neutrophil functions by administration of recombinant human granulocyte colony-stimulating factor in patients with malignant lymphoma. Blood, 74: 2743–2748, 1989.PubMedGoogle Scholar
  92. 92.
    Hansen PB, Kjaersgaard E, Johnsen HE, et al. Different membrane expression of CD1lb and CD 14 on blood neutrophils following in vivo administration of myeloid growth factors (published erratum appears in Br Haematol 1994 86: 240). Br J Haematol 85:50–56, 1993.PubMedCrossRefGoogle Scholar
  93. 93.
    Kerst JM, de Haas M, van der Schoot E, et al. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood 82: 3265–3272, 1993.PubMedGoogle Scholar
  94. 94.
    Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 78: 2791–2808, 1991.PubMedGoogle Scholar
  95. 95.
    Spertini O, Kansas GS, Munro JM, et al. Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin. Nature 349: 691–694, 1991.PubMedCrossRefGoogle Scholar
  96. 96.
    Liles WC, Rodger ER, Dale DC. Differential regulation of human neutrophil surface expression of CD14, CD1lb, CD18, and L-selectin following the administration of G-CSF in vivo and in vitro (abstract). Clin Res 42:304A, 1994.Google Scholar
  97. 97.
    Ohsaka A, Saionji K, Sato N, et al. Granulocyte colony-stimulating factor down-regulates the surface expression of the human leukocyte adhesion molecule-1 on human neutrophils in vitro and in vivo. Br J Haematol 84: 574–580, 1993.PubMedCrossRefGoogle Scholar
  98. 98.
    Ohsaka A, Saionji K, Igari J. Granulocyte colony-stimulating factor administration increases serum concentrations of soluble selectins. Br J Haematol 100: 66–69, 1998.PubMedCrossRefGoogle Scholar
  99. 99.
    Schleiffenbaum B, Spertini O, Tedder TF. Soluble L-selectin is present in human plasma at high levels and retains functional activity. J Cell Biol 119: 229–238, 1992.PubMedCrossRefGoogle Scholar
  100. 100.
    Spertini O, Callegari P, Cordey A-S, et al. High levels of the shed form of L-selectin are present in patients with acute leukemia and inhibit blast cell adhesion to activated endothelium. Blood 84: 1249–1256, 1994.PubMedGoogle Scholar
  101. 101.
    Fabian I, Kletter Y, Mor S, et al. Activation of human eosinophil and neutrophil functions by haemopoietic growth factors: comparisons of IL-1, IL-3, IL-5 and GM-CSF. Br J Haematol 80: 137–143, 1992.PubMedCrossRefGoogle Scholar
  102. 102.
    Burgess AW, Begley G, Johnson GR, et al. Purification and properties of bacterially synthesized human granulocyte-macrophage colony-stimulating factor. Blood 69: 43–51, 1987PubMedGoogle Scholar
  103. 103.
    Fleischman J, Golde DW, Weisbart RH, Gasson J. Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood 68: 708–711, 1986.Google Scholar
  104. 104.
    Richardson MD, Chung I. GM-CSF-modulated phagocytosis of Trichosporon beigelii by human neutrophils. J Med Microbiol 46: 321–325, 1997.PubMedCrossRefGoogle Scholar
  105. 105.
    Roilides E, Walsh TJ, Pizzo P, Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 163: 579–583, 1991.PubMedCrossRefGoogle Scholar
  106. 106.
    Katoh M, Takada M, Nakatani N, et al. Chemotaxis and phagocytosis of the neutrophils mobilized by granulocyte colony-stimulating factor in healthy donors for granulocyte transfusions. Am J Hematol 49: 96–97, 1995.PubMedCrossRefGoogle Scholar
  107. 107.
    Lawry J, Smith MO, Lorigan PC. Monitoring neutrophil phagocytosis in lung cancer patients or normal stem cell donors, treated with G-CSF. Biochem Soc Trans 25: 197S, 1997.Google Scholar
  108. 108.
    Stoppa AM, Fossat C, Sainty D, et al. In vivo administration of recombinant granulocyte colony-stimulating factor corrects acquired neutrophil function deficiency associated with chronic graft-versus-host disease. Br J Haematol 83: 169–170, 1993.PubMedCrossRefGoogle Scholar
  109. 109.
    Sullivan GW, Gelrud AK, Carper HT, et al. Interaction of tumor necrosis factor-α and granulocyte colony-stimulating factor on neutrophil apoptosis, receptor expression, and bactericidal function. Proc Assoc Amer Phys 108: 455–466, 1996.Google Scholar
  110. 110.
    Kerst JM, Van de Winkel GJ, Evans AH, et al. Granulocyte colony-stimulating factor induces hFcgRI (CD64 antigen)- positive neutrophils via an effect on myeloid precursor cells. Blood 81: 1457–1464, 1993.PubMedGoogle Scholar
  111. 111.
    Buckle AM, Jayaram Y, Hogg N. Colony-stimulating factors and interferon-γ differentially affect cell surface molecules shared by monocytes and neutrophils. Clin Exp Immunol 81: 339–342, 1990.PubMedCrossRefGoogle Scholar
  112. 112.
    Alerius T, Repp R, de Wit TPM, et al. Involvement of the high-affinity receptor for IgG (FcγRI CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 82: 931–939, 1993.Google Scholar
  113. 113.
    Ersten MJ, de Jong S, Evers LM, et al. Addition of granulocyte colony-stimulating factor to chemotherapy in patients with AIDS-related lymphoma: effects on neutrophil Fcg receptor expression and soluble FcgRIII plasma levels. Br J Haematol 99: 537–541, 1997.CrossRefGoogle Scholar
  114. 114.
    Ravetch JV, Kinet JP. Fc-receptors. Ann Rev Immunol 9: 457–492, 1991.CrossRefGoogle Scholar
  115. 115.
    Eisner J, Roesler J, Emmendoerffer A, et al. Altered function and surface marker expression of neutrophils induced by rhG-CSF treatment in severe congenital neutropenia. Eur J Haematol 48: 10–19, 1992.CrossRefGoogle Scholar
  116. 116.
    Maurer D, Fischer GF, Felzmann T, et al. Ratio of complement receptor over Fc-receptor III expression: a sensitive parameter to monitor granulocyte-macrophage colony-stimulating factor effects on neutrophils. Ann Hematol 62: 135–140, 1991.PubMedCrossRefGoogle Scholar
  117. 117.
    Nathan CF. Respiratory burst in adherent human neutrophils: triggering by colony-stimulating factors CSF-GM and CSF-G. Blood 73: 301–306, 1989.PubMedGoogle Scholar
  118. 118.
    Kitagawa S, You A, Souza LM, et al. Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by chemotactic peptide. Biochem Biophys Res Commun 144: 1143–1146, 1987.PubMedCrossRefGoogle Scholar
  119. 119.
    Weisbart RH, Golde DW, Clark SC, et al. Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. Nature 314: 361–363, 1985.PubMedCrossRefGoogle Scholar
  120. 120.
    Eisbart RH, Kwan L, Golde DW, Gasson JC. Human GM-CSF primes neutrophils for enhanced oxidative metabolism in response to the major physiological chemoattractants. Blood 69: 18–21, 1987.Google Scholar
  121. 121.
    Burt HM, Jackson JK. The priming action of tumor necrosis factor-alpha (TNF-α) and granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophils activated by inflammatory microcrystals. Clin Exp Immunol 108: 432–437, 1997.PubMedCrossRefGoogle Scholar
  122. 122.
    Meyer CN, Nielsen H. Priming of neutrophil and monocyte activation in human immunodeficiency virus infection. APMIS 104: 640–646, 1996.PubMedCrossRefGoogle Scholar
  123. 123.
    Balazovich KJ, Almeida HI, Boxer LA. Recombinant human G-CSF and GM-CSF prime human neutrophils for superoxide production through different signal transduction mechanisms. J Lab Clin Med 118: 576–584, 1991.PubMedGoogle Scholar
  124. 124.
    Liles WC, Rodger ER, Dale DC. In vivo administration of granulocyte colony-stimulating factor (G-CSF) to normal human subjects: priming of the respiratory burst and inhibition of apoptosis in neutrophils, (abstract) Blood 84: 24a, 1994.Google Scholar
  125. 125.
    Liles WC, Huang JE, van Burik J-A H, et al. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis 175: 1012–1015, 1997.PubMedCrossRefGoogle Scholar
  126. 126.
    Allen RC, Stevens PR, Price TH, et al. In vivo effects of recombinant human granulocyte colony-stimulating factor on neutrophil oxidative functions in normal human volunteers. J Infect Dis 175: 1184–1192, 1997.PubMedCrossRefGoogle Scholar
  127. 127.
    Lindermann A, Herrmann F, Oster W, et al. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 74: 2644–2651, 1989.Google Scholar
  128. 128.
    Harazmi A, Nielsen H, Hovgaard D, et al. Modulation of neutrophil and monocyte function by recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoma. Eur J Clin Invest 21:219–224, 1991.CrossRefGoogle Scholar
  129. 129.
    Kaplan SS, Basford RE, Wing EJ, Shadduck RK. The effect of recombinant human granulocyte-macrophage colony-stimulating factor on neutrophil activation in patients with refractory carcinoma. Blood 73: 636–638, 1989.PubMedGoogle Scholar
  130. 130.
    Wiltschke C, Krainer M, Nanut M, et al. In vivo administration of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor increases neutrophil oxidative burst activity. J Interf Cytok Res 15: 249–253, 1995.CrossRefGoogle Scholar
  131. 131.
    Uo A, Kitagawa S, Okabe T, et al. Recombinant human granulocyte colony-stimulating factor repairs the abnormalities of neutrophils in patients with myelodysplastic syndromes and chronic myelogenous leukemia. Blood 70: 404–411, 1987.Google Scholar
  132. 132.
    Iki S, Yuo A, Yagisawa M, et al. Increased neutrophil respiratory burst in myeloproliferative disorders: selective enhancement of superoxide release triggered by receptor-mediated agonists and low responsiveness to in vitro cytokine stimulation. Exp Hematol 25: 26–33, 1997.PubMedGoogle Scholar
  133. 133.
    Zabernigg A, Hilbe W, Eisterer W, et al. Cytokine priming of the granulocyte respiratory burst in myelodysplastic syndromes. Leukemia Lymphoma 27: 137–143, 1997.PubMedGoogle Scholar
  134. 134.
    Sato N, Kashima K, Tanaka Y, et al. Effect of granulocyte colony-stimulating factor on generation of oxygen-derived free radicals and myeloperoxidase activity in neutrophils from poorly controlled NIDDM patients. Diabetes 46: 133–137, 1997.PubMedCrossRefGoogle Scholar
  135. 135.
    Zimmerli W, Zarth A, Gratwohl A, et al. Granulocyte-macrophage colony-stimulating factor for granulocyte defects of bone marrow transplant patients. Lancet I: 494–497, 1989.Google Scholar
  136. 136.
    Roesler J, Emmendorffer A, Eisner J, et al. In vitro functions of neutrophils induced by treatment with rhG-CSF in severe congenital neutropenia. Eur J Haematol 46: 112–118, 1991.PubMedCrossRefGoogle Scholar
  137. 137.
    Eisner J, Roesler J, Emmendoerffer A, et al. Abnormal regulation in the signal transduction in neutrophils from patients with severe congenital neutropenia: relation of impaired mobilization of cytosolic free calcium to altered chemotaxis, superoxide anion generation and F-actin content. Exp Hematol 21:38–46, 1993.Google Scholar
  138. 138.
    Fabian I, Kletter Y, Bleiberg I, et al. Effect of exogenous recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor on neutrophil function following allogeneic bone marrow transplantation. Exp Hematol 19: 868–873, 1991.PubMedGoogle Scholar
  139. 139.
    Kowanko IC, Ferrante A, Harvey DP, et al. Granulocyte-macrophage colony-stimulating factor augments neutrophil killing of Torulopsis glabrata and stimulates neutrophil respiratory burst and degranulation. Clin Exp Immunol 83: 225–230, 1991.PubMedCrossRefGoogle Scholar
  140. 140.
    Vecchiarelli A, Monari C, Baldeiii F, et al. Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. J Infect Dis 171: 1448–1454, 1995.PubMedCrossRefGoogle Scholar
  141. 141.
    Roilides E, Uhlig K, Venzon D, et al. Neutrophil respiratory burst in response to blastoconidia and pseudohyphae of Candida albicans. J Infect Dis 166: 668–673, 1992.PubMedCrossRefGoogle Scholar
  142. 142.
    Roilides E, Holmes A, Blake C, et al. Effects of granulocyte colony-stimulating factor and interferon-γ on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species. J Leukoc Biol 57: 651–656, 1995.PubMedGoogle Scholar
  143. 143.
    Roilides E, Uhlig K, Venzon D, et al. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infectlmmun 61: 1185–1193, 1993.Google Scholar
  144. 144.
    Fossat C. Stoppa AM, Sainty D, et al. G-CSF in vivo improves neutrophil bactericidal activity against Pseudomonas aeruginosa in cancer patients, (abstract) Blood 76: 137a, 1990.Google Scholar
  145. 145.
    Glaspy JA, Baldwin JC, Robertson PA, et al. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 109: 789–795, 1988.PubMedGoogle Scholar
  146. 146.
    Mayer P, Lam C, Obenaus H, et al. Recombinant human GM-CSF induces leukocytosis and activates peripheral blood polymorphonuclear neutrophils in non-human primates. Blood 70: 206–213, 1987.PubMedGoogle Scholar
  147. 147.
    Baldwin GC, Fuller ND, Roberts RL, et al. Graanulocyte- and granulocyte-macrophage colony-stimulating factors enhance neutrophil cytotoxicity toward HIV-infected cells. Blood 74: 1673–1677, 1989.PubMedGoogle Scholar
  148. 148.
    Baldwin GC, Chung GY, Kaslander C, et al. Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumor cells. Br J Haematol 83: 545–553, 1993.PubMedCrossRefGoogle Scholar
  149. 149.
    Metcalf D, Begley CG, Johnson GR, et al. Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulatimg factor. Blood 67: 37–45, 1986.PubMedGoogle Scholar
  150. 150.
    Baldwin GC, Gasson JC, Quan SG, et al. Granulocyte-macrophage colony-stimulating factor enhances the neutrophil function in acquired immunodeficiency syndrome patients. Proc Natl Acad Sci USA 1988 85:2763–2766.PubMedCrossRefGoogle Scholar
  151. 151.
    Carlson M, Peterson C, Venge P. The influence of IL-3, IL-5, and GM-CSF on normal human eosinophil and neutrophil C3b-induced degranulation. Allergy 48: 437–442, 1993.PubMedGoogle Scholar
  152. 152.
    Sato N, Mizukami H, Tani K, Asano S. Regulation of mRNA levels of alkaline phosphatase gene in neutrophilic granulocytes by granulocyte colony-stimulating factor and retinoic acid. Eur J Haematol 46: 107–111, 1991.PubMedCrossRefGoogle Scholar
  153. 153.
    Sato N, Takatani O, Koeffler HP, et al. Modulation by retinoids and interferons of alkaline phosphatase activity in granulocytes induced by granulocyte colony-stimulating factor. Exp Hematol 17: 258–262, 1989.PubMedGoogle Scholar
  154. 154.
    Tsakona CP, Goldstone AH. Patterns of primary degranulation as indicated by the mean myeloperoxidase index (MPXI) during bacteremia in lymphoma transplants treated with growth factors. Clin Lab Haematol 14: 273–280, 1992.PubMedCrossRefGoogle Scholar
  155. 155.
    Ziegler-Heitbrock HWL, Ulevitch RJ. CD14: cell surface receptor and differentiation marker. Immunol Today 14: 121–125, 1993.PubMedCrossRefGoogle Scholar
  156. 156.
    Ellis RE, Yuan J, Horvitz HR. Mechanisms and functions of cell death. Annu Rev Cell Biol 7: 663–698, 1991.PubMedCrossRefGoogle Scholar
  157. 157.
    Newman SL, Henson JE, Henson PM. Phagocytosis of senescent neutrophils by human monocyte-derived macrophages and rabbit inflammatory macrophages. J Exp Med 156: 430–442, 1982.PubMedCrossRefGoogle Scholar
  158. 158.
    Savill JS, Wyllie AH, Henson JE, et al. Macrophage phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 83: 865–875, 1989.PubMedCrossRefGoogle Scholar
  159. 159.
    Cohen JJ. Programmed cell death in the immune system. Adv Immunol 50: 55–85, 1991.PubMedCrossRefGoogle Scholar
  160. 160.
    Cohen JJ, Duke RC, Fadok VA, Sellins KS. Apoptosis and programmed cell death in immunity. Annu Rev Immunol 10: 267–293, 1992.PubMedCrossRefGoogle Scholar
  161. 161.
    Dransfield I, Buckle A, Savill A, et al. Neutrophil apoptosis is associated with reduction in CD 16 (FcγRIII) expression. J Immunol 153: 1254–1263, 1994.PubMedGoogle Scholar
  162. 162.
    Homburg CHE, de Haas M, Von dem Borne AEG, et al. Human neutrophils lose their surface FcgRIII and acquire annexin V binding sites during apoptosis in vitro. Blood 85: 532–540, 1995.PubMedGoogle Scholar
  163. 163.
    Dransfield I, Stocks SC, Haslett C. Regulation of cell adhesion molecule expression and function associated with neutrophil apoptosis. Blood 85: 3264–3273, 1995.PubMedGoogle Scholar
  164. 164.
    Whyte MKB, Meagher LC, MacDermot J, Haslett C. Impairment of function in aging neutrophils is associated with apoptosis. J Immunol 150: 5124–5134, 1993.PubMedGoogle Scholar
  165. 165.
    Colotta F, Re F, Polentarutti N, et al. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80: 2012–2020, 1992.PubMedGoogle Scholar
  166. 166.
    Liles WC, Kiener PA, Ledbetter JA, et al. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 184:429–440, 1996.PubMedCrossRefGoogle Scholar
  167. 167.
    Lee A, Whyte MKB, Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol 54: 283–288, 1993.PubMedGoogle Scholar
  168. 168.
    Hu B, Yasui K. Effects of colony-stimulating factors (CSFs) on neutrophil apoptosis: possible roles at inflammatory site. Int J Hematol 66: 179–188, 1997.PubMedCrossRefGoogle Scholar
  169. 169.
    Gasmi L, McLennan AG, Edwards S. The diadenosine polyphosphates Ap3A and Ap4 A and adenosine triphosphate interact with granulocyte-macrophage colony-stimulating factor to delay neutrophil apoptosis: implications for neutrophil:platelet interactions during inflammation. Blood 87: 3442–3449, 1996.PubMedGoogle Scholar
  170. 170.
    Gasmi L, McLennan AG, Edwards S. Neutrophil apoptosis is delayed by the diadenosine polyphosphates, Ap5A and A6 A: synergism with granulocyte-macrophage colony-stimulating factor. Br J Haematol 95: 637–639, 1996.PubMedCrossRefGoogle Scholar
  171. 171.
    Niessen H, Meisenholder GW, Li HL, et al. Granulocyte colony-stimulating factor upregulates the vacuolar proton ATPase in human neutrophils. Blood 90: 4598–4601, 1997.PubMedGoogle Scholar
  172. 172.
    Liles WC, Dale DC, Klebanoff SJ. Fas (APO-1 CD95) activation induces apoptosis in human phagocytes, (abstract) Blood 84: 371a, 1994.Google Scholar
  173. 173.
    Iwai K, Miyawaki T, Taakizawa T, et al. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 84: 1201–1208, 1994.PubMedGoogle Scholar
  174. 174.
    Matsumoto K, Schleimer RP, Saito H, et al. Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood 86: 1437–1443, 1995.PubMedGoogle Scholar
  175. 175.
    Liles WC, Dale DC, Klebanoff SJ. Glucocorticoids inhibit apoptosis of human neutrophils. Blood 86:3181–3188, 1995.PubMedGoogle Scholar
  176. 176.
    Pitrak DL, Tsai HC, Mullane KM, et al. Accelerated neutrophil apoptosis in the acquired immunodeficiency syndrome. J Clin Invest 98: 2714–2719, 1996.PubMedCrossRefGoogle Scholar
  177. 177.
    Adachi S, Kubota M, Lin YW, et al. In vivo administration of granulocyte colony-stimulating factor promotes neutrophil survival in vitro. Eur J Haematol 53: 129–134, 1994.PubMedCrossRefGoogle Scholar
  178. 178.
    Matute-Bello G, Liles WC, Radella II F, et al. Neutrophil apoptosis in the acute respiratory distress syndrome. Am J Respir Crit Care Med 156: 1969–1977, 1997.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • J. Milton Gaviria
  • W. Conrad Liles
  • David C. Dale

There are no affiliations available

Personalised recommendations